Lipid lowering drug and other toxic myopathies

被引:7
|
作者
Schoser, BGH [1 ]
Pongratz, D [1 ]
机构
[1] Univ Munich, Neurol Klin, Friedrich Baur Inst, D-80336 Munich, Germany
来源
INTERNIST | 2005年 / 46卷 / 11期
关键词
myopathy; toxic myopathy; lipid lowering drug myopathy; rhabdomyolysis;
D O I
10.1007/s00108-005-1490-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A growing number of therapeutic agents and exogenous toxins are harmful to structure and function of human skeletal muscle. The clinical syndrome encompasses asymptomatic creatine kinase elevation, myalgia, exercise intolerance, muscle paresis and atrophy, and lastly acute rhabdomyolysis. Toxic myopathies are potentially reversible, hence a prompt recognition is particularly helpful for the early diagnosis and in conclusion elimination of a myopathy inducing toxin. Toxic myopathies may be classified as acute or chronic accordingly to the exposition time to a toxin. Main source of an exogenous induced toxic myopathy is chronic alcohol abuse. Alcohol excess induces acute and/or chronic neuropathy and myopathy, consequently muscle wasting and weakness occurs. Drug-induced myopathies are most frequently seen due to amplified utilization of corticosteroids or lipid lowering agents.
引用
收藏
页码:1198 / +
页数:7
相关论文
共 50 条
  • [31] Update on Toxic Myopathies
    Mastaglia, F. L.
    Needham, M.
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2012, 12 (01) : 54 - 61
  • [32] Toxic myopathies: Overview
    Khelfi, Abderrezak
    Azzouz, Mohamed
    Abtroun, Rania
    Reggabi, Mohamed
    Alamir, Berkahoum
    TOXICOLOGIE ANALYTIQUE ET CLINIQUE, 2016, 28 (03) : 187 - 199
  • [33] Update on Toxic Myopathies
    F. L. Mastaglia
    M. Needham
    Current Neurology and Neuroscience Reports, 2012, 12 : 54 - 61
  • [34] Iatrogenic and toxic myopathies
    Sieb, JP
    Gillessen, T
    MUSCLE & NERVE, 2003, 27 (02) : 142 - 156
  • [35] Lipid Myopathies
    Pennisi, Elena Maria
    Garibaldi, Matteo
    Antonini, Giovanni
    JOURNAL OF CLINICAL MEDICINE, 2018, 7 (12)
  • [36] FLUVASTATIN IN COMBINATION WITH OTHER LIPID-LOWERING AGENTS
    JOKUBAITIS, LA
    BRITISH JOURNAL OF CLINICAL PRACTICE, 1994, : 28 - 32
  • [37] Update on statins and other lipid-lowering drugs
    Miller, CA
    GERIATRIC NURSING, 2001, 22 (05) : 276 - 277
  • [38] Hepatotoxicity of statins and other lipid-lowering agents
    Bjornsson, Einar S.
    LIVER INTERNATIONAL, 2017, 37 (02) : 173 - 178
  • [39] Other Myopathies
    Hussain, Yessar
    Miller, Samantha
    NEUROLOGIC CLINICS, 2020, 38 (03) : 619 - 635
  • [40] Lipid-lowering Drug Therapy in Elderly Patients
    Berthold, Heiner K.
    Gouni-Berthold, Ioanna
    CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (09) : 877 - 893